NASDAQ:ALXN
Delisted

Alexion Pharmaceuticals Stock Price (Quote)

$182.50
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $182.50 $182.50 Friday, 27th May 2022 ALXN stock ended at $182.50. During the day the stock fluctuated 0% from a day low at $182.50 to a day high of $182.50.
90 days $182.50 $182.50
52 weeks $174.72 $187.45

Historical Alexion Pharmaceuticals prices

Date Open High Low Close Volume
2019-03-27 $136.71 $137.50 $133.10 $134.60 1 106 432
2019-03-26 $133.15 $136.95 $132.61 $136.79 1 737 728
2019-03-25 $130.29 $132.34 $128.30 $132.29 1 684 001
2019-03-22 $133.86 $134.90 $130.10 $130.21 1 512 041
2019-03-21 $130.47 $134.56 $130.03 $134.21 1 729 770
2019-03-20 $133.20 $133.56 $130.85 $131.66 1 702 945
2019-03-19 $133.57 $134.56 $132.39 $132.94 1 005 729
2019-03-18 $136.04 $136.39 $132.86 $133.51 1 744 496
2019-03-15 $135.31 $136.65 $134.62 $136.09 2 070 737
2019-03-14 $135.87 $136.38 $133.48 $134.88 1 361 377
2019-03-13 $135.22 $136.96 $134.48 $135.71 1 066 753
2019-03-12 $132.55 $134.87 $131.79 $134.30 1 560 978
2019-03-11 $128.97 $132.20 $128.35 $132.04 1 306 377
2019-03-08 $127.26 $128.77 $125.70 $128.68 1 194 344
2019-03-07 $131.18 $131.20 $126.71 $128.17 1 667 303
2019-03-06 $134.57 $134.90 $130.60 $131.12 1 241 863
2019-03-05 $136.15 $136.50 $134.26 $134.77 1 030 273
2019-03-04 $138.00 $138.32 $133.39 $136.08 1 502 223
2019-03-01 $132.89 $137.80 $132.66 $137.75 1 445 884
2019-02-28 $135.58 $137.30 $134.37 $135.33 1 556 101
2019-02-27 $132.49 $136.19 $132.00 $136.01 1 131 456
2019-02-26 $131.85 $134.95 $131.85 $133.29 1 396 553
2019-02-25 $130.50 $133.37 $130.50 $133.17 1 574 532
2019-02-22 $127.93 $129.85 $126.86 $129.73 1 221 577
2019-02-21 $129.63 $130.09 $126.30 $127.55 1 019 720
Click to get the best stock tips daily for free!

About Alexion Pharmaceuticals

Alexion Pharmaceuticals Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosp... ALXN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT